Revenue
No reported data
Lantern Pharma Inc. (LTRN)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Research & development | $11.5M | $16.1M | $11.9M | $8.6M | $7.6M | $2.2M | — |
| Operating expenses | $18.0M | $22.2M | $17.9M | $14.4M | $12.6M | $5.9M | $2.4M |
| Operating income | −$18.0M | −$22.2M | −$17.9M | −$14.4M | −$12.6M | — | — |
| EBITDAderived | −$18.0M | −$22.2M | −$17.9M | −$14.4M | −$12.6M | — | — |
| Net income | −$17.1M | −$20.8M | −$16.0M | −$14.3M | −$12.4M | −$5.9M | −$2.4M |
| Basic EPSper diluted share | -$1.57 | -$1.93 | -$1.47 | -$1.31 | -$1.13 | -$1.37 | -$1.23 |
| Diluted EPSper diluted share | -$1.57 | -$1.93 | -$1.47 | -$1.31 | -$1.13 | -$1.37 | -$1.23 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 12, 2026Form 4 | Schalop Lee TroyDirector | BuyCommon stock, $0.001 par value | 48.5K | $2.06 | $100.0K | 48.5K |
| May 12, 2026Form 4 | Schalop Lee TroyDirector | BuyCommon stock purchase warrant (Right to Buy) · derivative | 48.5K | $0.00 | $0.00 | 48.5K |
| May 12, 2026Form 4 | KEYSER D JEFFREYDirector | BuyCommon stock, $0.001 par value | 48.5K | $2.06 | $100.0K | 94.3K |
| May 12, 2026Form 4 | KEYSER D JEFFREYDirector | BuyCommon stock purchase warrant (Right to Buy) · derivative | 48.5K | $0.00 | $0.00 | 48.5K |
| Jun 13, 2025Form 4 | BIOS Fund II QP, LP +9TenPercentOwner | SellCommon Stock · indirect | 4.4K | $3.09 | $13.5K | 114.3K |